Fig 1: AREG in the human ovary. A Representative images of IHC staining of AREG, CYP17A1, and LHCGR in the early-mid follicle phase. Scale bar: 150 μm, 200 μm, 1 mm; GCs, granulosa cells; TCs, theca cells. B Representative images of double immunofluorescent staining of AREG (red) and CYP17A1 (green), or AREG (red) and FSHR (green) in human theca cells and granulosa cells isolated in follicular fluid during oocyte retrieval after hCG trigger. Nuclei were stained with DAPI (blue). Scale bar: 50 μm
Fig 2: Immunoprecipitation followed by western blotting and dot blot analysis of anti-FSHR autoantibodies in the serum of the patient. A polyclonal antibody against FSHR (Abcam, ab113421) in TBST buffer (containing 3% BSA) was used as positive control serum with anti-FSHR autoantibodies, a healthy person’s serum was used as negative control, and sera from the patient before and after the dexamethasone treatment were used to immunoprecipitate recombinant FSHR protein purified from E. coli (ImmunoClone, IC8974-A). Samples comprising 0.6 μg of FSHR protein per well were separated on 10% SDS-PAGE gels and then transferred to nitrocellulose membranes. For the dot blot assay, FSHR protein (100 ng/dot) was applied onto nitrocellulose membranes. The membranes were incubated overnight at 4 °C with serum from the patient and the healthy control, followed by incubation with a horseradish peroxidase (HRP)-conjugated anti-human secondary antibody (Proteintech, SA00001–11) or anti-rabbit secondary antibody (Proteintech, SA00001–2). Stained bands or dots were visualized using Omni-ECL reagent (EpiZyme, SQ201). PC: positive control; BD: before the dexamethasone treatment; AD: after the dexamethasone treatment. NC: negative control; FSHR: follicle-stimulating hormone receptor
Fig 3: Identification of human theca cells. A Representative images of IHC staining for CYP17A1 in ovarian tissues collected from follicle fluid during oocyte retrieval. In the control group, samples were treated in the same manner, but normal rabbit IgG was used instead of the primary antibodies. Scale bar: 100 μm. B Representative images of IF staining for CYP17A1 (green) and FSHR (green) in the isolated cells. In the control group, samples were treated in the same manner, but PBS was used instead of the primary antibodies. Nuclei were stained with DAPI (blue). Scale bar: 250 μm
Fig 4: Expression of miR-7a in the mouse ovary.(A) The expression of miR-7a in the ovaries of mice at 6–8 weeks of age was detected by the ISH method. (B) miR-7a was adjusted from purple/ blue to red fluorescence. (C)Triple -immunofluorescence of adult mice ovary sections: miR-7a (red), FSHR (green), DDX4 (pink), and DAPI (blue); yellow is the merge of red and green. (D) The negative control of (A). Bars: 50 μm.
Fig 5: Crystallographic image of the extracellular domain of the FSHR (blue, beige, yellow) folding over its ligand FSH (orange), adapted from Jiang et al. (22). In yellow the beta strands/leucine-rich repeat domains in amino acid stretch C18-N187 are highlighted, against which the polyclonal anti-FSHR antibody MBS178821 is raised. The blue ribbon represent the amino acids that exon 9 codes for, which lacks in the short FSHR variant.
Supplier Page from Abcam for Anti-FSH-R antibody